Discoveries

Covering the Full Spectrum of
Hemato-oncology

Blood tumors pose a serious threat to human health, ranging from myeloma, non-Hodgkin’s lymphoma to leukemia.
InnoCare’s scientists have been making every effort to combat blood tumors by developing a variety of small molecule and large molecule drugs.

Focusing on Huge Unmet Needs

InnoCare has focused a lot of effort on autoimmune diseases, a particular area with huge unmet needs.

InnoCare has fortified its powerful discovery engine on cutting-edge global targets for the development of autoimmune therapeutics through B-cell and T-cell pathways, with the aim of delivering first-in-class and/or best-in-class treatments to address the massive unmet clinical needs and strong market potential in China and globally.

BTK

TYK2

VAV1

IL-17

Reinforce Competitiveness

Our drug discovery team has been constantly exploring better technologies and achieving exceptional innovations in target discovery, compound screening, and the selection of drug candidates, enabling us to develop excellent drug molecules with high selectivity and safety.

Orelabrutinib

BTK Inhibitor
Highly Selective, Covalent
Approved for Marketing

Soficitinib（ICP-332）

Novel TYK2 inhibitor
Reversible, Highly Selective
Inhibiting TYK2 kinase activity

Zurletrectinib (ICP-723)

pan-TRK Inhibitor
Reversible, Highly Selective
Inhibiting NTRK Gene Fusion

R&D Areas

Solid Tumors

Building a Competitive Drug Portfolio

InnoCare has been building a robust and diversified portfolio to address significant unmet medical needs across multiple tumor types. InnoCare’s proprietary ADC technology platform, alongside promising precision medicine candidates like zurletrectinib, positions the Company to establish a strong presence in the field of solid tumor treatment.

Autoimmune Diseases

Developing B-cell and T-cell Pathways in Autoimmune Diseases

Hemato-oncology

Building a Leading Franchise in Hemato-oncology

InnoCare continued to strengthen its leading franchise in hemato-oncology with orelabrutinib approved for four indications and successfully included in the NRDL, while tafasitamab became the first CD19 antibody approved for the treatment of r/r DLBCL in China. Mesutoclax (ICP-248), the first BCL2 inhibitor granted BTD in China, continues to advance across multiple indications, including CLL/SLL, MCL, AML and MDS, with clinical trials ongoing in China and globally.